ПРЕПРИНТ
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.
Проведено выборочное изучение серопревалентности к вирусу SARS-CoV-2 среди 348 медицинских работников (МР) 10 медицинских организаций г. Казани: многопрофильных стационаров, которые были перепрофилированы для оказания медицинской помощи больным коронавирусной инфекцией (МС 1-7), станции скорой медицинской помощи (СМП1), медицинской организации, осуществляющей амбулаторно-поликлиническую деятельность (АПП1) и специализированной поликлиники (СП1). Для определения IgG использовался твердофазный ИФА. Доля МР различных медицинских организаций г. Казани серопревалентность по IgG антителам к вирусу SARS-CoV-2 составляет 16,4 %. Широкое варьирование значения серопревалентности групп МР различных медицинских организаций (3.3-30.8%) может свидетельствовать о разном уровне эффективности противоэпидемических мероприятий в данных учреждения. Сравнительно низкая доля положительных анализов на антитела к вирусу SARS-CoV-2 у МР специализированной поликлиники (6.1%) может свидетельствовать об эффекте весеннего карантина. В целом по группе МР с серопозитивными результатами отмечается превалирование доли с очень высоким коэффициентом позитивности (49,1%), что характеризует высокую напряжённость иммунного ответа. Отмечена корреляция между величиной серопревалентности у МР медицинской организации с долей положительных сывороток, показавших большие коэффициенты позитивности.
Решетникова И. Д., Тюрин Ю. А., Агафонова Е. В., Куликов С. Н., Гилязутдинова Г. Ф., Лопушов Д. В., Шайхразиева Н. Д., Исаева Г. Ш., Зиатдинов В. Б. 2020. Опыт изучения коллективного и персонального иммунитета к вирусу SARS-CoV-2 у медицинских работников. COVID19-PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111801
1. 1.Tao Liu, Sanyun Wu, Huangheng Tao, Guang Zeng, Fuling Zhou, Fangjian Guo, Xinghuan Wang. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan - implications for the ability to 13 produce long-lasting protective antibodies against SARS-CoV-2 doi: https://doi.org/10.1101/2020.06.13.20130252.
2. Xang F., Wang X., He X.et al. Antibody detection and dynamic characteristics in Patients with COVID-19. Clin Infect Dis. 2020 Apr 19: ciaa461. doi: 10.1093/cid/ciaa461.
3. Zhao J., Yuan Q., Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 [published online ahead of print, 2020 Mar 28]. Clin Infect Dis., 2020, ciaa344. https://doi.org/10.1093/cid/ciaa344.
4. Semenov A.V., Pshenichnaya N.YU. Uroki epidemii COVID-19 v Italii. Infekciya i immunitet 2020, T. 10, № 3, s. 410–420
5. Semenov A.V., Pshenichnaya N.Yu., Rozhdennaya v Uhani: uroki epidemii COVID-19 v Kitae. Infekciya i immunitet 2020, T. 10, no 2, s. 210–220]
6. The novel coronavirus pneumonia emergency response epidemiology team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases COVID-19. China CCDC Weekly, 2020, no. 2, pp. 1–10. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51 (02.04.2020).
7. V. V. Kutyrev, A. Yu. Popova, V. Yu. Smolenskiy, E.B. Ezhlova, Yu. V. Demina, V. A. Safronov, I. G. Karnaukhov, A. V. Ivanova, S. A. Shcherbakova Epidemiological features of the new coronavirus infection (COVID-19). Message 2: features of the course of the COVID-19 epidemic process in conjunction with the ongoing anti-epidemic measures in the world and the Russian Federation. Problems of especially dangerous infections. 2020 2: 6-12. https://doi.org/10.21055/0370-1069-2020-2-6-12
8. 8. Lombardi A., Consonni D., Carugno M., Bozzi G., Mangioni D., Muscatello A., Castelli V., Palomba E., Cantù A.P. Ceriotti F., Tiso B., Pesatori A.C., Riboldi L., Bandera A., Gori A. Characteristics of 1,573 healthcare workers who underwent nasopharyngeal swab for SARS-CoV-2 in Milano, Lombardy, Italy. [Электронный ресурс]. URL: https://www.medrxiv.org/content/10.1101/2020.05.07.200942 76v1 (дата обращения 15.06.2020).
9. Takita M., Matsumura T., Yamamoto K., Yamashita E., Hosoda K., Hamaki T., Kusumi E. Preliminary Results of Seroprevalence of SARS-CoV-2 at Community Clinics in Tokyo. [Электронный ресурс]. URL: https://www.medrxiv.org/content/10 .1101/2020.04.29.20085449v1 (дата обращения 15.06.2020).
10. Liu T., Wu S., Tao H., Zeng G., Zhou F., Guo F., Wang X. Prevalence of IgG antibodies toSARS-CoV-2 in Wuhan - implications for the ability to produce long-lasting protective antibodies against. SARS-CoV-2. medRxiv., 2020.06.13.20130252; https://doi.org/10.1101/2020.06.13.20130252/
11. 11.Korth J, Wilde B, Dolff S, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. JClin Virol. 2020;128:104437. doi:10.1016/j.jcv.2020.104437
12. 12.Schmidt SB, Grüter L, Boltzmann M, Rollnik JD. Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff. PLoS One. 2020;15(6):e0235417. doi:10.1371/journal.pone.0235417
13. 13.Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11(1):3500. doi:10.1038/s41467-020-17318-x
14. Базыкина Е.А., Троценко О.Е. Эпидемиологическое значение бессимптомныхносителей covid-19 (обзор литературы) https://doi.org/10.21055/preprints-3111765
15. 15.Corradini P, Gobbi G, de Braud F, et al. Rapid Antibody Testing for SARSCoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections. Hemasphere. 2020;4(3):e408. doi:10.1097/HS9.0000000000000408
16. Hains DS, Schwaderer AL, Carroll AE, Starr MC, Wilson AC, Amanat F, et al. Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. JAMA. 2020 May 14: e208438. DOI:10.1001/jama.2020.8438
17. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N Engl J Med.2020;382(22):2158-2160. doi:10.1056/NEJMe2009758
18. Popova A.Yu., Ezhlova E.B., Mel'nikova A.A, Bashketova N.S., Fridman R.K., Lyalina L.V., Smirnov V.S., CHkhindzheriya I.G., Grechaninova T.A., Agapov K.A., Arsent'eva N.A., Bazhenova N.A., Bacunov O.K, Danilova E.M., Zueva E.V., Komkova D.V., Kuznecova R.N., Lyubimova N.E., Markova A.N., Hamitova I.V., Milichkina A.M., Dedkov V.G., Totolyan A.A. Populyacionnyj immunitet k virusu SARS-CoV-2 sredi naseleniya Sankt-Peterburga v aktivnuyu fazu epidemii COVID-19 2020 (v pechati). https://doi.org/10.21055/preprints-3111752.
19. Popova A. Yu., Ezhlova E.B., Mel'nikova A. A., Istorik O. A., Mosevich O. S., Lyalina L.V., Smirnov V. S., Chernyj M. A., Balabysheva N. S., Loginova I.S., Vladimirova O. S., Samoglyadova I.S., Vasev N.A., Rumyanceva S. V., CHupalova E. YU., Selivanova G.V., Murav'eva M.V., Timofeeva L.V., Hankishieva E.N., Tyl'chevskaya V.D., Nikitenko N.D., Kostenickaya T.I., Virkunen N.V., Klimkina I.M., Kuz'mina T.M., Degtyarenko N.V., Bazunova A.I., Filippova L.A., Pal'chikova N.A., Kukshkin A.V., Arsent'eva N.A., Bacunov O.K., Bogumil'chik E.A., Voskresenskaya E. A., Drobyshevskaya V.G., Zueva E.V., Kokorina G.I., Kurova N.N., Lyubimova N.E., Ferman R.S., Hamdulaeva G.N., Hamitova I.V., Hor'kova E.V., Milichkina A.M., Dedkov V.G., Totolyan A.A. Opyt ocenki populyacionogo immuniteta k SARS-cov-2 sredi naseleniya leningradskoj oblasti v period epidemii Covid-19. bc.com/Russian/features-53094577. https://doi.org/10.21055/preprints-3111753
20. Протокол популяционного стратифицированного по возрасту сероэпидемиологического исследования инфекции COVID-19 у человека Версия: 2.0 Дата: 26 мая 2020 г. WHO/2019-nCoV/Seroepidemiology/2020.2. Protokol populyacionnogo stratificirovannogo po vozrastu seroepidemiologicheskogo issledovaniya infekcii COVID-19 u cheloveka Versiya: 2.0 Data: 26 maya 2020 g. WHO/2019-nCoV/Seroepidemiology/2020.2 ( in Rus).
21. 21.Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020 May 6. DOI: 10.1001/ jama.2020.8259.
22. 22.Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Apr 29. DOI: 10.1038/s41591-020-0897-1.
23. 23.Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Preprint at medRxiv. Available from: https://doi.org/10.1101/2020.03.30.20047365.
24. COVID-19-EPIDEMIC : Immunity after SARS-CoV-2 infection– a rapid review. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/immunity-after-sars-cov-2 infection-1st-update-report-2020
25. Contribution of asymptomatic and pre-symptomatic cases of COVID-19 in spreading virus and targeted control strategies]. Zhonghua Liu Xing BingXue Za Zhi. 2020;41(6):801-805. Chinese. doi: 10.3760/cma.j.cn112338-20200406-00517. PMID: 32274917
26. Wu Z, McGoogan JM. Asymptomatic and Pre-Symptomatic COVID-19 inChina. Infect Dis Poverty. 2020;9(1):72. doi:10.1186/s40249-020-00679-2;
27. Huff HV, Singh A. Asymptomatic transmission during the COVID-19pandemic and implications for public health strategies. Clin Infect Dis.2020;ciaa654. doi:10.1093/cid/ciaa654
28. 13.Al-Tawfiq JA. Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19). Travel Med Infect Dis. 2020;35:101608. doi:10.1016/j.tmaid.2020.101608
29. Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020;53(3):404-412. doi:10.1016/j.jmii.2020.02.012 3
30. Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections with COVID-19. J Microbiol Immunol Infect. 2020;10.1016/j.jmii.2020.05.001. doi:10.1016/j.jmii.2020.05.001
31. Yu X, Yang R. COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir Viruses. 2020;14(4):474- 475. doi:10.1111/irv.12743
32. 31.Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative. Ann Intern Med. 2020;M20-3012. doi:10.7326/M20-3012
33. 32.Hosoki K, Chakraborty A, Sur S. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. J Allergy Clin Immunol. 2020;S0091-6749(20)30799-5. doi:10.1016/j.jaci.2020.05.033
34. Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections with COVID-19. J Microbiol Immunol Infect. 2020;10.1016/j.jmii.2020.05.001. doi:10.1016/j.jmii.2020.05.001
35. В. В. Кутырев, А. Ю. Попова, В. Ю. Смоленский, Е. Б. Ежлова, Ю. В. Демина, В. А. Сафронов, И. Г. Карнаухов, А. В. Иванова, С. А. ЩербаковаЭпидемиологические особенности новой коронавирусной инфекции (COVID-19). Сообщение 2: особенности течения эпидемического процесса COVID-19 во взаимосвязи с проводимыми противоэпидемическими мероприятиями в мире и Российской Федерации https://doi.org/10.21055/0370-1069-2020-2-6-12Problemy Osobo Opasnykh Infektsii [Problems of Particularly Dangerous Infections]. 2020; 2; 6-12.
36. Медуницын Н.В., Олефир Ю.В., Меркулов В.А., Бондарев В.П. Персональный и коллективный иммунитет при вакцинации. БИОпрепараты. Профилактика, диагностика, лечение. 2016;16(4):195-207. Medunitsyn N.V., Olefir Y.V., Merkulov V.A., Bondarev V.P. Vaccination contribute to the development of personal and herd immunity. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(4):195-207.
37. Природно-очаговые инфекции в Казани и лесах г.Казани и Прикамскго региона:коллективная монография/ В. А. Бойко., В. А. Потапов., В. С. Трифонов [и др.]. Казань: Медицина, 2011.110 C. Prirodno-ochagovye infekcii v Kazani i lesah g.Kazani i Prikamskgo regiona:kollektivnaya monografiya/ V. A. Bojko., V. A. Potapov., V. S. Trifonov [i dr.]. Kazan': Medicina, 2011.110 C
38. References:
39. 1.Tao Liu, Sanyun Wu, Huangheng Tao, Guang Zeng, Fuling Zhou, Fangjian Guo, Xinghuan Wang. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan - implications for the ability to 13 produce long-lasting protective antibodies against SARS-CoV-2 doi: https://doi.org/10.1101/2020.06.13.20130252.
40. Xang F., Wang X., He X.et al. Antibody detection and dynamic characteristics in Patients with COVID-19. Clin Infect Dis. 2020 Apr 19: ciaa461. doi: 10.1093/cid/ciaa461.
41. Zhao J., Yuan Q., Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 [published online ahead of print, 2020 Mar 28]. Clin Infect Dis., 2020, ciaa344. https://doi.org/10.1093/cid/ciaa344.
42. Semenov A.V., Pshenichnaya N.YU. Uroki epidemii COVID-19 v Italii. Infekciya i immunitet 2020, T. 10, № 3, s. 410–420
43. Semenov A.V., Pshenichnaya N.Yu., Rozhdennaya v Uhani: uroki epidemii COVID-19 v Kitae. Infekciya i immunitet 2020, T. 10, no 2, s. 210–220]
44. The novel coronavirus pneumonia emergency response epidemiology team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases COVID-19. China CCDC Weekly, 2020, no. 2, pp. 1–10. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51 (02.04.2020).
45. V. V. Kutyrev, A. Yu. Popova, V. Yu. Smolenskiy, E.B. Ezhlova, Yu. V. Demina, V. A. Safronov, I. G. Karnaukhov, A. V. Ivanova, S. A. Shcherbakova Epidemiological features of the new coronavirus infection (COVID-19). Message 2: features of the course of the COVID-19 epidemic process in conjunction with the ongoing anti-epidemic measures in the world and the Russian Federation. Problems of especially dangerous infections. 2020 2: 6-12. https://doi.org/10.21055/0370-1069-2020-2-6-12
46. Lombardi A., Consonni D., Carugno M., Bozzi G., Mangioni D., Muscatello A., Castelli V., Palomba E., Cantù A.P. Ceriotti F., Tiso B., Pesatori A.C., Riboldi L., Bandera A., Gori A. Characteristics of 1,573 healthcare workers who underwent nasopharyngeal swab for SARS-CoV-2 in Milano, Lombardy, Italy. [Электронный ресурс]. URL: https://www.medrxiv.org/content/10.1101/2020.05.07.200942 76v1 (дата обращения 15.06.2020).
47. Takita M., Matsumura T., Yamamoto K., Yamashita E., Hosoda K., Hamaki T., Kusumi E. Preliminary Results of Seroprevalence of SARS-CoV-2 at Community Clinics in Tokyo. [Электронный ресурс]. URL: https://www.medrxiv.org/content/10 .1101/2020.04.29.20085449v1 (дата обращения 15.06.2020).
48. Liu T., Wu S., Tao H., Zeng G., Zhou F., Guo F., Wang X. Prevalence of IgG antibodies toSARS-CoV-2 in Wuhan - implications for the ability to produce long-lasting protective antibodies against. SARS-CoV-2. medRxiv., 2020.06.13.20130252; https://doi.org/10.1101/2020.06.13.20130252/
49. 11.Korth J, Wilde B, Dolff S, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. JClin Virol. 2020;128:104437. doi:10.1016/j.jcv.2020.104437
50. 12.Schmidt SB, Grüter L, Boltzmann M, Rollnik JD. Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff. PLoS One. 2020;15(6):e0235417. doi:10.1371/journal.pone.0235417
51. 13.Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11(1):3500. doi:10.1038/s41467-020-17318-x
52. Bazykina E.A., Trotsenko O.E. Epidemiological significance of asymptomatic carriers of covid-19 (literature review) https://doi.org/10.21055/preprints-311176515.
53. Corradini P, Gobbi G, de Braud F, et al. Rapid Antibody Testing for SARSCoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections. Hemasphere. 2020;4(3):e408. doi:10.1097/HS9.0000000000000408
54. Hains DS, Schwaderer AL, Carroll AE, Starr MC, Wilson AC, Amanat F, et al. Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. JAMA. 2020 May 14: e208438. DOI:10.1001/jama.2020.8438
55. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N Engl J Med.2020;382(22):2158-2160. doi:10.1056/NEJMe2009758
56. Popova A.Yu., Ezhlova E.B., Mel'nikova A.A, Bashketova N.S., Fridman R.K., Lyalina L.V., Smirnov V.S., CHkhindzheriya I.G., Grechaninova T.A., Agapov K.A., Arsent'eva N.A., Bazhenova N.A., Bacunov O.K, Danilova E.M., Zueva E.V., Komkova D.V., Kuznecova R.N., Lyubimova N.E., Markova A.N., Hamitova I.V., Milichkina A.M., Dedkov V.G., Totolyan A.A. Populyacionnyj immunitet k virusu SARS-CoV-2 sredi naseleniya Sankt-Peterburga v aktivnuyu fazu epidemii COVID-19 2020 (v pechati). https://doi.org/10.21055/preprints-3111752.
57. Popova A. Yu., Ezhlova E.B., Mel'nikova A. A., Istorik O. A., Mosevich O. S., Lyalina L.V., Smirnov V. S., Chernyj M. A., Balabysheva N. S., Loginova I.S., Vladimirova O. S., Samoglyadova I.S., Vasev N.A., Rumyanceva S. V., CHupalova E. YU., Selivanova G.V., Murav'eva M.V., Timofeeva L.V., Hankishieva E.N., Tyl'chevskaya V.D., Nikitenko N.D., Kostenickaya T.I., Virkunen N.V., Klimkina I.M., Kuz'mina T.M., Degtyarenko N.V., Bazunova A.I., Filippova L.A., Pal'chikova N.A., Kukshkin A.V., Arsent'eva N.A., Bacunov O.K., Bogumil'chik E.A., Voskresenskaya E. A., Drobyshevskaya V.G., Zueva E.V., Kokorina G.I., Kurova N.N., Lyubimova N.E., Ferman R.S., Hamdulaeva G.N., Hamitova I.V., Hor'kova E.V., Milichkina A.M., Dedkov V.G., Totolyan A.A. Opyt ocenki populyacionogo immuniteta k SARS-cov-2 sredi naseleniya leningradskoj oblasti v period epidemii Covid-19. bc.com/Russian/features-53094577. https://doi.org/10.21055/preprints-3111753
58. Protocol for a population-based age-stratified sero-epidemiological study of COVID-19 infection in humans Version: 2.0 Date: May 26, 2020. WHO/2019-nCoV/Seroepidemiology/2020.2
59. 21.Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020 May 6. DOI: 10.1001/ jama.2020.8259.
60. 22.Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Apr 29. DOI: 10.1038/s41591-020-0897-1.
61. 23.Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Preprint at medRxiv. Available from: https://doi.org/10.1101/2020.03.30.20047365.
62. COVID-19-EPIDEMIC : Immunity after SARS-CoV-2 infection– a rapid review. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/immunity-after-sars-cov-2 infection-1st-update-report-2020
63. Contribution of asymptomatic and pre-symptomatic cases of COVID-19 in spreading virus and targeted control strategies]. Zhonghua Liu Xing BingXue Za Zhi. 2020;41(6):801-805. Chinese. doi: 10.3760/cma.j.cn112338-20200406-00517. PMID: 32274917
64. Wu Z, McGoogan JM. Asymptomatic and Pre-Symptomatic COVID-19 inChina. Infect Dis Poverty. 2020;9(1):72. doi:10.1186/s40249-020-00679-2;
65. Huff HV, Singh A. Asymptomatic transmission during the COVID-19pandemic and implications for public health strategies. Clin Infect Dis.2020;ciaa654. doi:10.1093/cid/ciaa654
66. 13.Al-Tawfiq JA. Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19). Travel Med Infect Dis. 2020;35:101608. doi:10.1016/j.tmaid.2020.101608
67. Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020;53(3):404-412. doi:10.1016/j.jmii.2020.02.012 3
68. Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections with COVID-19. J Microbiol Immunol Infect. 2020;10.1016/j.jmii.2020.05.001. doi:10.1016/j.jmii.2020.05.001
69. Yu X, Yang R. COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir Viruses. 2020;14(4):474- 475. doi:10.1111/irv.12743
70. 31.Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative. Ann Intern Med. 2020;M20-3012. doi:10.7326/M20-3012
71. 32.Hosoki K, Chakraborty A, Sur S. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. J Allergy Clin Immunol. 2020;S0091-6749(20)30799-5. doi:10.1016/j.jaci.2020.05.033
72. Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections with COVID-19. J Microbiol Immunol Infect. 2020;10.1016/j.jmii.2020.05.001. doi:10.1016/j.jmii.2020.05.001
73. Medunitsyn N.V., Olefir Yu.V., Merkulov V.A., Bondarev V.P. Personal and collective immunity during vaccination. BIOPreparations. Prevention, diagnosis, treatment. 2016; 16 (4): 195-207.
74. Prirodno-ochagovye infekcii v Kazani i lesah g.Kazani i Prikamskgo regiona:kollektivnaya monografiya/ V. A. Bojko., V. A. Potapov., V. S. Trifonov [i dr.]. Kazan': Medicina, 2011.110 C
